BML 4.99 Decreased By ▼ -0.02 (-0.4%)
BOP 12.94 Decreased By ▼ -0.14 (-1.07%)
CNERGY 7.19 Increased By ▲ 0.07 (0.98%)
CPHL 88.00 Increased By ▲ 0.55 (0.63%)
DCL 14.68 Increased By ▲ 0.34 (2.37%)
DGKC 173.10 Increased By ▲ 2.34 (1.37%)
FCCL 46.91 Increased By ▲ 0.15 (0.32%)
FFL 16.13 Increased By ▲ 0.31 (1.96%)
GCIL 27.00 Increased By ▲ 0.13 (0.48%)
HUBC 146.79 Increased By ▲ 2.61 (1.81%)
KEL 5.17 Increased By ▲ 0.10 (1.97%)
KOSM 6.62 Decreased By ▼ -0.07 (-1.05%)
LOTCHEM 20.69 Increased By ▲ 0.10 (0.49%)
MLCF 85.75 Increased By ▲ 1.02 (1.2%)
NBP 122.40 Increased By ▲ 0.58 (0.48%)
PAEL 44.12 Increased By ▲ 0.66 (1.52%)
PIAHCLA 22.30 Increased By ▲ 0.01 (0.04%)
PIBTL 9.00 Increased By ▲ 0.07 (0.78%)
POWER 14.14 Increased By ▲ 0.13 (0.93%)
PPL 170.25 Increased By ▲ 0.31 (0.18%)
PREMA 42.95 Decreased By ▼ -0.44 (-1.01%)
PRL 33.27 Increased By ▲ 0.16 (0.48%)
PTC 23.97 Decreased By ▼ -0.29 (-1.2%)
SNGP 119.20 Decreased By ▼ -0.44 (-0.37%)
SSGC 46.36 Increased By ▲ 0.81 (1.78%)
TELE 8.15 Increased By ▲ 0.07 (0.87%)
TPLP 10.46 Decreased By ▼ -0.01 (-0.1%)
TREET 24.00 Increased By ▲ 0.03 (0.13%)
TRG 57.99 Decreased By ▼ -0.06 (-0.1%)
WTL 1.53 Increased By ▲ 0.01 (0.66%)
BR100 13,732 Increased By 100.9 (0.74%)
BR30 40,150 Increased By 299.2 (0.75%)
KSE100 135,442 Increased By 1141.9 (0.85%)
KSE30 41,157 Increased By 342.6 (0.84%)
World

Pfizer, Moderna COVID vaccines appear effective against Indian variants: Research

  • As per lab experiments involving cell cultures, the B.1.617 and B.1.618 variants seem to be partially resistant to the antibodies developed by the vaccination
  • Researchers say the vaccine's antibodies are a little bit weaker against the variants, but not to an extent that it would have much of an effect on the protective ability of the vaccines
Published May 18, 2021

(Karachi) The coronavirus vaccines developed by biotechnology giants, Pfizer and Moderna, appear to protect against triple-mutant coronavirus variants from India, B.1.617 and B.1.618, researchers have revealed.

The recent study has been carried out by the New York University Grossman School of Medicine and NYU Langone Center and is considered preliminary because it has not yet been published in a peer-reviewed journal.

As per lab experiments involving cell cultures, the B.1.617 and B.1.618 variants seem to be partially resistant to the antibodies developed by the vaccination.

Researchers said that there is a good reason to believe that vaccinated individuals will remain protected against the B.1.617 and B.1.618 variants.

They added that the vaccine's antibodies are a little bit weaker against the variants, but not to an extent that it would have much of an effect on the protective ability of the vaccines.

Earlier, the World Health Organization reclassified the highly contagious triple-mutant Covid variant spreading in India as a “variant of concern,” indicating that it’s become a global health threat.

WHO's Technical Lead for COVID-19, Maria Van Kerkhove said the variant, known as B.1.617, has been found in preliminary studies to spread more easily than the original virus and there is some evidence it may able to evade some of the protections provided by vaccines.

“And as such we are classifying this as a variant of concern at the global level,” she said.

Kerkhove stated, “Even though there is increased transmissibility demonstrated by some preliminary studies, we need much more information about this virus variant in this lineage in all of the sub-lineages, so we need more sequencing, targeted sequencing to be done.”

Comments

Comments are closed.